Search
nirogacestat (Ogsiveo)
Indications:
- progressive, unresectable, recurrent, or refractory desmoid tumors in adults [1]
Contraindications:
- pregnancy: can cause fetal harm
Dosage:
- 150 mg BID until disease progression or unacceptable tocixity
tablets 50 mg
Pharmacokinetics:
- protein bindin 99%m 95% to albumin
- bioavailability 18%
- induces CYP2B6, CYP2C8, CYP2C9, & CYP2C19
- excreted in feces (38%), urine (17%), expirwd air (9.7%)
- mean terminal 1/2 life 23 hours
Adverse effects:
- diarrhea (84%), nausea (54%), fatigue (51%)
- hypophosphatemia (42%)
- maculopapular rash (32%)
- cough
- alopecia
- increased serum transaminases, hypokalemia
- proteinuria, glucosuria
- transient ovarian dysfunction in most women of childbearing age
Drug interactions:
- strong or moderate CYP3A inhibitors increase nirogacestat
- strong or moderate CYP3A inducers decrease nirogacestat
- antacids
Mechanism of action:
- gamma secretase inhibitor
General
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations
References
- Otto MA
FDA Approves Nirogacestat for Desmoid Tumors.
Medscape. November 27, 2023
https://www.medscape.com/viewarticle/998820
- Highlights of Prescribing Information
Ogsiveonirogacestat tablets for oral use
https://springworkstx.com/wp-content/uploads/2023/11/OGSIVEO-US-Prescribing-Information-11.27.23.pdf